Tuesday, July 1, 2025 7/1/2025

Prediction of imminent sudden cardiac death based on warning signs

Award Number: R01HL147358
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/04/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2025

Group Awards By:

View Award Description

Prediction of imminent sudden cardiac death based on warning signs - Sudden cardiac arrest (SCA), a sudden catastrophic loss of the pulse, affects >350,000 in the US annually. Most will suffer sudden cardiac death (SCD) within 10 minutes of presentation, yielding a mortality rate >90%. Based on our recent work, we have proposed a novel paradigm for SCD called “near-term prevention”. SCA is often not as sudden as one might expect. At least 50% of individuals will have warning symptoms at some time in the 4 weeks prior to SCD, but these can be non-specific, so are often not acted upon. The overall goal of this proposal is to refine the identification of the symptomatic individual at high-risk of SCD, during this 4-week window of opportunity. We propose that a simultaneous examination of symptoms, clinical factors and biomarkers may identify individuals at highest risk of imminent SCD, which could enable prediction and pre-emptive management, thereby preventing SCD. We are proposing to develop a comprehensive risk score from two population-based studies founded by the PI. The Portland, Oregon Sudden Unexpected Death Study (Oregon-SUDS, catchment area ≈ 1 million) is now in its 17th year and the Ventura, California PRESTO study (Prediction of Sudden Death in Multi-Ethnic Communities, catchment area ≈ 850,000) is in its 5th year. The resulting combined databank contains information on >7500 SCD cases and controls, with detailed clinical phenotyping and a biobank of plasma samples. From Oregon-SUDS, we recently reported that 51% (n=430) of 839 individuals who suffered SCD presented with at least one symptom within the 4 weeks prior to their lethal event. The main symptom was chest pain, but dyspnea, fatigue, syncope and palpitations were also recorded. Warning signs could represent an opportunity for near-term prediction of SCD. While these symptoms are common and may be non-specific for SCD, we hypothesize that a combination of specific symptoms and clinical profile could facilitate the identification of patients at high risk of impending SCA. In addition, the discovery of novel plasma biomarkers for SCD could have additional utility for risk stratification. We therefore hypothesize that biomarkers, when combined with specific symptoms and clinical profile, will maximize the likelihood of identifying symptomatic subjects at highest risk of SCD, allowing for early intervention. SCD remains a major public health problem with a critical need for novel prediction and prevention. Development of this user-friendly risk score for imminent SCD in those with warning symptoms would represent a practical and clinically meaningful advance for triage of patients for optimal care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	000	4	6/16/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $790,673 )
2023	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	000	4	2/24/2023	NON-COMPETING CONTINUATION	$790,673
														Subtotal = $790,673

Issue Date FY: 2022 ( Subtotal = $791,174 )
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	001	3	6/18/2022	NON-COMPETING CONTINUATION	$79,121
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	000	3	2/14/2022	NON-COMPETING CONTINUATION	$712,053
														Subtotal = $791,174

Issue Date FY: 2021 ( Subtotal = $800,448 )
2021	2021	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	000	2	3/3/2021	NON-COMPETING CONTINUATION	$800,448
														Subtotal = $800,448

Issue Date FY: 2020 ( Subtotal = $816,401 )
2020	2020	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cardiovascular Diseases Research	000	1	3/4/2020	NEW	$816,401
														Subtotal = $816,401

Grand Total All Awards = $3,198,696

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prediction of imminent sudden cardiac death based on warning signs

Award Number: R01HL147358

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/04/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer